Loading...
Ligand Pharmaceuticals, Inc.
LGNDZ•PNK
HealthcareMedical - Pharmaceuticals
$0.004
$0.001(43.40%)
Ligand Pharmaceuticals, Inc. (LGNDZ) Stock Overview
Explore Ligand Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
27.28%
↑ 27.28%
Profit Growth
$-6.91
↓ 107.73%
EPS Growth
$-6.91
↓ 107.28%
Operating Margin
-34.06%
↓ 289.30%
ROE
-16.36%
↓ 107.73%
Dividend Yield
0.00%
Analyst Recommendations data is not available for LGNDZAnalyst Recommendations details for LGNDZ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
CEO
Mr. Todd C. Davis Ph.D.
Employees
68
Founded
1970